Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma

BRAF mutations occur in about 50% of melanoma patients. FDA approved BRAF and MEK inhibitors have improved the prognosis of patients with BRAF mutations. However, all responders develop resistance typically within one year of treatment. Recent observations demonstrate that BRAF inhibitors induce rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Long, Mishra, Rosalin, Patel, Hima, Abdulsalam, Safnas, Greis, Kenneth D., Kadekaro, Ana Luisa, Merino, Edward J., Garrett, Joan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299399/
https://www.ncbi.nlm.nih.gov/pubmed/30588251
http://dx.doi.org/10.7150/jca.27295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299399/
https://www.ncbi.nlm.nih.gov/pubmed/30588251
http://dx.doi.org/10.7150/jca.27295

Ejemplares similares